A PHASE III STUDY OF BMS-188667 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS

Phase 1

Completed

• Conditions: -M069; M069

• Registration Number: PER-086-02
• Lead Sponsor: BRISTOL MYERS SQUIBB PERU S.A.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2002-12-30
• Last Update Posted: 2023-09-04

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Meet criteria of American Rheumatism Association for the diagnosis of rheumatoid arthritis and the American College of Rheumatology functional classes I, II III or IV
Participants must be taking 1 or more DMARDs and/or biologic approved for rheumatoid arthritis (RA) for at least 3 months and be on a stable dose for 28 days prior to Day 1.

Exclusion Criteria

Other auto-immune disease as a main diagnosis (e.g. Systemic Lupus Erythematosus [SLE], Scleroderma)
Active tuberculosis (TB) requiring treatment within last 3 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified